Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better?

Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better?

Abstract Background Pharmacological corticosteroid therapy is the standard of care in Duchenne Muscular Dystrophy (DMD) that aims to control symptoms and slow disease progression through potent anti-inflammatory action. However, a major concern is the significant adverse effects associated with long...

Full description

Bibliographic Details
Main Authors: Stephanie Kourakis, Cara A. Timpani, Dean G. Campelj, Patricia Hafner, Nuri Gueven, Dirk Fischer, Emma Rybalka
Format: Article
Language:English
Published: BMC 2021-03-01
Series:Orphanet Journal of Rare Diseases
Subjects:
Duchenne muscular dystrophy
Corticosteroids
Standard of care
Anti-inflammatory drugs
Anti-inflammation
Online Access:https://doi.org/10.1186/s13023-021-01758-9

Internet

https://doi.org/10.1186/s13023-021-01758-9

Similar Items